Disclosed are triazolopyrazine derivatives of formula I wherein the substituents are disclosed within the specification or a pharmaceutically acceptable salt thereof. Also disclosed is the use of a pharmaceutical composition comprising a compound of formula I for treatment of c-Met related disorders in mammals.